Do you work in the area of immuno-oncology? If so, join us for a group discussion about the current progress and challenges in the field, led by Eurofins Discovery lead scientists. Meet experts and local researchers in the field at this invite-only event. In true SDBN fashion, we will host a networking activity aimed at helping you build your network. The field of immuno-oncology is moving quickly, and you need to connect with the latest science and others working in the field.
Join us at BioLabs San Diego, 9620 Towne Centre Dr Ste 100, San Diego, CA 92121 (map link), from 5:00 p.m.-8:00 p.m. Tuesday November 19th. Eurofins is a founding partner of BioLabs, come see our new offices!
|5:00-5:30 p.m.||Welcome, Casual Dinner & Wine|
|5:30-6:00 p.m.||Robust and Reproducible Target Biology-Based Bioassays for Therapeutics Targeting Checkpoint Modulators
A quantitative and robust bioassay that is reflective of the MOA of the drug is a critical component of any development program. PathHunter® cell-based assay platform offers ready to use bioassays for potency determination & stability testing of biological drugs. These quantitative and robust assays rely on the native biology of the relevant receptor, allowing developers to choose a readout reflective of the MOA of their drug. Importantly, since these are homogeneous assays that employ thaw-and-use cryopreserved cells, they not only provide convenience while minimizing assay variability, they are also highly scalable and suitable for automation. We will share case studies from our expanding portfolio of qualified bioassays for several immune-oncology targets. (read more & speaker bio)
|Alpana Prasad, Ph.D. Senior Strategic Portfolio Manager at Eurofins DiscoverX|
|6:00-7:00 p.m.||Networking Activity|
|7:00-7:30 p.m.||BioMAP® Human Tumor Microenvironment Models to Support Immuno-Oncology Drug Discovery
In the past decade, immunotherapies have revolutionized the treatment options for cancers resistant or recalcitrant to more conventional approaches. Approved immuno-oncology (IO) drugs that restore a patient’s capacity to mount an anti-cancer immune response have achieved compelling clinical successes. However, improved objective response rates (ORR) are limited to a minority of patients (10%-30%), depending on cancer type. Expanding IO efficacy has prompted intense efforts to develop new IO therapies and enhanced combination strategies. Early implementation of innovative and translationally relevant target validation plus IO qualification assays and services is critical to more fully deliver on the promise of IO strategies. (read more & speaker bio)
Alison O’Mahony, PhD. Vice President Translational Biology Eurofins Discovery
|7:30-8:00 p.m.||Networking & Dessert|
Host & Location
|BioLabs San Diego, 9620 Towne Centre Dr Ste 100, San Diego, CA 92121 (map link)|
Eurofins Discovery Chats are the brainchild of Sonela Cavicke, Director of Business Development at Eurofins Discovery, and Mary Canady, SDBN Founder and Sr. Director, Equality Excellence at Eurofins. Mary and Sonela are two leaders of the Eurofins Equality Driving Excellence Team, which aims to leverage programs surrounding equality to attract new hires and improve the success and well being of all employees. We are integrating the Equality Driving Excellence objectives into each Discovery Chat event, from speaker selection, to networking activities, to featuring open positions at the company.